|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
IL155002A0
(en)
*
|
2000-10-12 |
2003-10-31 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
US20030138417A1
(en)
*
|
2001-11-08 |
2003-07-24 |
Kaisheva Elizabet A. |
Stable liquid pharmaceutical formulation of IgG antibodies
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
|
CN1671741A
(zh)
*
|
2002-06-21 |
2005-09-21 |
拜奥根Idec公司 |
浓缩抗体的缓冲剂制剂及其使用方法
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
|
AU2004216298B2
(en)
|
2003-02-28 |
2009-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized protein-containing formulations
|
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
DK1610820T4
(da)
*
|
2003-04-04 |
2013-11-04 |
Genentech Inc |
Høj-koncentration antistof- og proteinformuleringer
|
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
CA2544532C
(en)
*
|
2003-11-28 |
2015-06-16 |
Micromet Ag |
Compositions comprising polypeptides
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
CN1956738B
(zh)
|
2004-01-09 |
2013-05-29 |
辉瑞大药厂 |
MAdCAM抗体
|
|
US20060008415A1
(en)
*
|
2004-06-25 |
2006-01-12 |
Protein Design Labs, Inc. |
Stable liquid and lyophilized formulation of proteins
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1838854B1
(en)
|
2004-12-15 |
2012-10-31 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize Beta Amyloid Peptide
|
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
CA2595380A1
(en)
*
|
2005-01-28 |
2006-08-03 |
Wyeth |
Stabilized liquid polypeptide formulations
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
DK1865986T3
(en)
*
|
2005-03-08 |
2016-04-11 |
Pfizer Prod Inc |
The anti-CTLA-4 antibody compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
ES2633574T3
(es)
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
|
CA2607663C
(en)
*
|
2005-05-19 |
2014-08-12 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
EP1909831A4
(en)
|
2005-06-14 |
2013-02-20 |
Amgen Inc |
SELF-BUFFING PROTEIN FORMULATIONS
|
|
WO2007002543A2
(en)
*
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
CA2615731A1
(en)
*
|
2005-07-29 |
2007-02-08 |
Amgen Inc. |
Formulations that inhibit protein aggregation
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
US20100209437A1
(en)
*
|
2005-09-12 |
2010-08-19 |
Greg Elson |
Anti-CD3 Antibody Fromulations
|
|
KR101105871B1
(ko)
*
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
|
CA2625998C
(en)
*
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
WO2007076062A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
|
EP2029132A4
(en)
|
2006-01-25 |
2011-07-27 |
Taro Pharmaceuticals North America Inc |
ANTIHISTAMINE COMPOSITIONS AND THEIR USE
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
EP2738178A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
DK2011880T3
(da)
|
2006-04-13 |
2012-11-26 |
Chugai Pharmaceutical Co Ltd |
Taurin transportergen
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
GEP20125628B
(en)
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
|
AU2014268186C1
(en)
*
|
2006-04-26 |
2017-12-07 |
Wyeth Llc |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
AU2016204760A1
(en)
*
|
2006-04-26 |
2016-07-28 |
Wyeth Llc |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
SI2944306T1
(sl)
|
2006-06-16 |
2021-04-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
AU2012200284B2
(en)
*
|
2006-10-06 |
2014-03-06 |
Amgen Inc. |
Stable Antibody Formulations
|
|
PE20081179A1
(es)
*
|
2006-10-06 |
2008-09-29 |
Amgen Inc |
Formulaciones estables de anticuerpos egfr
|
|
CA2666492C
(en)
|
2006-10-20 |
2012-07-17 |
Douglas Rehder |
Stable polypeptide formulations
|
|
JP5577098B2
(ja)
*
|
2006-12-21 |
2014-08-20 |
アムジエン・インコーポレーテツド |
ポリペプチドを含有する安定な緩衝化された製剤
|
|
WO2008114673A1
(ja)
|
2007-03-15 |
2008-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
ポリペプチドの製造方法
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
US20100189721A1
(en)
*
|
2007-07-06 |
2010-07-29 |
Smithkline Beecham Corporation |
Antibody formulations
|
|
JP5889529B2
(ja)
|
2007-07-27 |
2016-03-22 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
アミロイド原性疾患の処置
|
|
US8697397B2
(en)
|
2007-08-07 |
2014-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method of producing heterogeneous protein
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
RU2505603C2
(ru)
|
2007-09-26 |
2014-01-27 |
Чугаи Сейяку Кабусики Кайся |
Антитело против рецептора il-6
|
|
BRPI0818039A2
(pt)
|
2007-10-15 |
2014-10-14 |
Chugai Pharmaceutical Co Ltd |
Método para produzir uma célula capaz de produção de alto rendimento de heteroproteínas.
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
AU2008314973C1
(en)
*
|
2007-10-24 |
2014-05-08 |
Chugai Seiyaku Kabushiki Kaisha |
A cell for use in production of heteroproteins and production method using the same
|
|
EP3381445B1
(en)
*
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
EP2240156A2
(en)
*
|
2007-12-28 |
2010-10-20 |
BioInvent International AB |
Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
|
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
SG2014011365A
(en)
*
|
2008-09-19 |
2014-05-29 |
Hoffmann La Roche |
Novel antibody formulation
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
CN104398471A
(zh)
*
|
2008-11-28 |
2015-03-11 |
Abbvie公司 |
稳定的抗体组合物和用于稳定其的方法
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
CA2754528A1
(en)
*
|
2009-03-06 |
2010-09-10 |
Genetech, Inc. |
Antibody formulation
|
|
WO2010115728A2
(en)
*
|
2009-03-30 |
2010-10-14 |
F. Hoffmann-La Roche Ag |
A method for avoiding glass fogging
|
|
EP2423309B1
(en)
|
2009-04-22 |
2018-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
A method for producing a cell capable of high-yield production of heteroproteins
|
|
NZ613809A
(en)
*
|
2009-05-04 |
2015-02-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
EP2453874A2
(en)
*
|
2009-07-14 |
2012-05-23 |
Biogen Idec MA Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
CA2726232A1
(en)
*
|
2009-07-16 |
2010-08-12 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
AU2010286427A1
(en)
|
2009-08-31 |
2012-03-08 |
Abbott Biotherapeutics Corp. |
Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
|
|
PT2473528E
(pt)
*
|
2009-09-03 |
2015-03-04 |
Ablynx NV |
Formulações estáveis de polipéptidos e seus usos
|
|
US8821879B2
(en)
|
2009-09-04 |
2014-09-02 |
Xoma Technology Ltd. |
Anti-botulism antibody coformulations
|
|
EP2473191B1
(en)
*
|
2009-09-04 |
2017-08-23 |
XOMA Technology Ltd. |
Antibody coformulations
|
|
BR112012011463A2
(pt)
|
2009-10-30 |
2017-05-02 |
Abbott Biotherapeutics Corp |
uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
|
|
CA2783715A1
(en)
*
|
2009-12-29 |
2011-07-07 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
|
ES2905545T3
(es)
|
2010-01-06 |
2022-04-11 |
Takeda Pharmaceuticals Co |
Proteínas de unión a calicreína plasmática
|
|
US20120294866A1
(en)
*
|
2010-01-19 |
2012-11-22 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for proteins
|
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
|
RU2626512C2
(ru)
|
2010-03-01 |
2017-07-28 |
Цитодин, Инк. |
Концентрированные белковые фармацевтические составы и их применение
|
|
SG183443A1
(en)
|
2010-03-01 |
2012-09-27 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
|
ES2614807T3
(es)
|
2010-06-04 |
2017-06-02 |
Wyeth Llc |
Formulaciones vacunales
|
|
FR2961107B1
(fr)
*
|
2010-06-15 |
2012-07-27 |
Lab Francais Du Fractionnement |
Composition d'immunoglobulines humaines stabilisee
|
|
JP6055412B2
(ja)
*
|
2010-09-17 |
2016-12-27 |
バクスアルタ ゲーエムベーハー |
弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
|
|
JO3400B1
(ar)
|
2010-09-30 |
2019-10-20 |
Ferring Bv |
مركب صيدلاني من كاربيتوسين
|
|
WO2012061448A1
(en)
|
2010-11-04 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Anti-il-23 antibodies
|
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
|
EP2471554A1
(en)
*
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
|
IL269565B2
(en)
|
2011-01-06 |
2024-06-01 |
Dyax Corp |
Plasma kallikrein binding proteins
|
|
MX385629B
(es)
|
2011-01-13 |
2025-03-18 |
Regeneron Pharma |
Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
|
|
MX2013010737A
(es)
|
2011-03-25 |
2014-03-12 |
Genentech Inc |
Novedosos metodos de purificacion de proteinas.
|
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
AU2012275233A1
(en)
*
|
2011-06-30 |
2013-11-28 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
|
SG11201401360XA
(en)
|
2011-10-25 |
2014-05-29 |
Onclave Therapeutics Ltd |
Antibody formulations and methods
|
|
NZ629204A
(en)
*
|
2012-02-16 |
2016-09-30 |
Santarus Inc |
Anti-vla1 (cd49a) antibody pharmaceutical compositions
|
|
US11078265B2
(en)
*
|
2012-05-03 |
2021-08-03 |
Boehringer Ingelheim International Gmbh |
Anti-IL-23 antibodies
|
|
MY188825A
(en)
|
2012-05-18 |
2022-01-06 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
|
MX2015000337A
(es)
*
|
2012-07-09 |
2015-09-25 |
Coherus Biosciences Inc |
Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
|
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
MX2015003007A
(es)
|
2012-09-07 |
2015-06-05 |
Coherus Biosciences Inc |
Formulaciones acuosas estables de adalimumab.
|
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
UA117466C2
(uk)
*
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
BR112015023086A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
|
|
EP2970502A4
(en)
|
2013-03-15 |
2016-11-30 |
Dyax Corp |
ANTI-PLASMA KALLIKREIN ANTIBODY
|
|
CN105377892A
(zh)
|
2013-03-15 |
2016-03-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
|
KR20150132332A
(ko)
|
2013-03-15 |
2015-11-25 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
저농도 항체 제형
|
|
CN103217525B
(zh)
*
|
2013-03-21 |
2015-04-29 |
上海执诚生物科技股份有限公司 |
一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
|
|
KR20140119396A
(ko)
|
2013-03-29 |
2014-10-10 |
삼성전자주식회사 |
단백질 약물의 액상 제형
|
|
US10745475B2
(en)
|
2013-08-30 |
2020-08-18 |
Takeda Gmbh |
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
|
|
DK3071237T3
(da)
|
2013-11-21 |
2024-09-09 |
Genmab As |
Lyofiliseret formulering af antistoflægemiddelkonjugat
|
|
KR102424183B1
(ko)
|
2014-01-21 |
2022-07-26 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
|
|
EP3122782A4
(en)
|
2014-03-27 |
2017-09-13 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
|
BR112016025126B1
(pt)
*
|
2014-05-07 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
|
|
TWI694836B
(zh)
*
|
2014-05-16 |
2020-06-01 |
英商葛蘭素史克智慧財產管理有限公司 |
抗體調配物
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
|
US20160074515A1
(en)
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
|
EP3157942B1
(en)
|
2014-06-23 |
2020-06-17 |
Novartis AG |
Site specific protein modifications
|
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|
|
WO2015198199A1
(en)
|
2014-06-23 |
2015-12-30 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof.
|
|
WO2016014775A1
(en)
|
2014-07-24 |
2016-01-28 |
Boehringer Ingelheim International Gmbh |
Biomarkers useful in the treatment of il-23a related diseases
|
|
WO2016036918A1
(en)
|
2014-09-03 |
2016-03-10 |
Boehringer Ingelheim International Gmbh |
Compound targeting il-23a and tnf-alpha and uses thereof
|
|
MX382408B
(es)
|
2014-10-24 |
2025-03-13 |
Merck Sharp & Dohme Llc |
Coagonistas de los receptores de glucagón y de glp-1.
|
|
DK4268843T3
(da)
|
2014-11-07 |
2025-11-10 |
F Hoffmann La Roche Ltd |
Forbedrede IL-6-antistoffer
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
AU2016209968B2
(en)
|
2015-01-23 |
2018-11-29 |
Novartis Ag |
Synthetic apelin fatty acid conjugates with improved half-life
|
|
BR112017014684A2
(en)
|
2015-02-04 |
2018-01-09 |
Boehringer Ingelheim International Gmbh |
methods of treatment of inflammatory diseases
|
|
CA2985001A1
(en)
|
2015-05-07 |
2016-11-10 |
Novimmune Sa |
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
|
|
US11091543B2
(en)
|
2015-05-07 |
2021-08-17 |
Swedish Orphan Biovitrum Ag |
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
EP3334747B1
(en)
|
2015-08-13 |
2023-09-27 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
CN114712497B
(zh)
|
2015-12-03 |
2024-03-22 |
雷杰纳荣制药公司 |
抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
|
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
|
CN116077648A
(zh)
|
2015-12-11 |
2023-05-09 |
武田药品工业株式会社 |
血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
|
|
WO2017109706A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
US12115227B2
(en)
|
2016-01-13 |
2024-10-15 |
Genmab A/S |
Formulation for antibody and drug conjugate thereof
|
|
US20190046642A1
(en)
*
|
2016-02-23 |
2019-02-14 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonist formulations and uses thereof
|
|
WO2017184880A1
(en)
|
2016-04-20 |
2017-10-26 |
Coherus Biosciences, Inc. |
A method of filling a container with no headspace
|
|
WO2018027195A1
(en)
*
|
2016-08-05 |
2018-02-08 |
Abbvie Biotherapeutics Inc. |
Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
|
|
AU2017345490B2
(en)
|
2016-10-21 |
2022-07-07 |
Amgen Inc. |
Pharmaceutical formulations and methods of making the same
|
|
WO2018080196A2
(ko)
|
2016-10-28 |
2018-05-03 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
WO2018156367A1
(en)
*
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
|
GB201703062D0
(en)
*
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
WO2018156180A1
(en)
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
|
TW202228779A
(zh)
*
|
2017-03-01 |
2022-08-01 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3603669B1
(en)
*
|
2017-03-31 |
2024-06-19 |
Meiji Seika Pharma Co., Ltd. |
Aqueous formulation, aqueous formulation in injector, antibody protein disaggregating agent, and antibody protein disaggregation method
|
|
EP3612217A4
(en)
*
|
2017-04-18 |
2020-12-30 |
Dr. Reddy's Laboratories Limited |
STABLE LIQUID PHARMACEUTICAL COMPOSITION
|
|
SG11201909955XA
(en)
|
2017-05-02 |
2019-11-28 |
Merck Sharp & Dohme |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7263256B6
(ja)
*
|
2017-05-16 |
2023-07-24 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ｐｄ－ｌ１抗体医薬組成物およびその使用
|
|
GB201708655D0
(en)
|
2017-05-31 |
2017-07-12 |
Ucb Biopharma Sprl |
Cell culture methods
|
|
SG11202000298VA
(en)
|
2017-07-14 |
2020-02-27 |
Pfizer |
Antibodies to madcam
|
|
AU2018328015A1
(en)
|
2017-09-05 |
2020-03-05 |
Merck Sharp & Dohme Corp. |
Compounds for reducing the viscosity of biological formulations
|
|
EP3684332A1
(en)
*
|
2017-09-18 |
2020-07-29 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
HUE059827T2
(hu)
|
2017-11-30 |
2023-01-28 |
Regeneron Pharma |
VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
|
|
CN119386161A
(zh)
|
2017-12-22 |
2025-02-07 |
诺华股份有限公司 |
用fgf21变体治疗代谢障碍的方法
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
UA130009C2
(uk)
|
2018-05-07 |
2025-10-15 |
Генмаб А/С |
Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
|
|
NZ770284A
(en)
|
2018-05-10 |
2025-11-28 |
Regeneron Pharma |
High concentration vegf receptor fusion protein containing formulations
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
CA3106669A1
(en)
*
|
2018-07-20 |
2020-01-30 |
Momenta Pharmaceuticals, Inc. |
Compositions of fcrn antibodies and methods of use thereof
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
JP2022513626A
(ja)
|
2018-11-26 |
2022-02-09 |
ノバルティス アーゲー |
Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
|
|
JP2022513693A
(ja)
*
|
2018-11-29 |
2022-02-09 |
ハーバー・バイオメド・セラピューティクス・リミテッド |
抗ｐｄ－ｌ１抗体製剤
|
|
WO2020152367A1
(en)
|
2019-01-25 |
2020-07-30 |
Ospedale San Raffaele S.R.L. |
Inhibitor of dux4 and uses thereof
|
|
US20220275061A1
(en)
*
|
2019-07-12 |
2022-09-01 |
Contrafect Corporation |
Therapeutic protein formulations comprising antibodies and uses thereof
|
|
US20210070852A1
(en)
*
|
2019-09-09 |
2021-03-11 |
Boehringer Ingelheim International Gmbh |
Anti-IL-23p19 Antibody Formulations
|
|
GB201913697D0
(en)
|
2019-09-23 |
2019-11-06 |
King S College London |
DAP10/DAP12 fusion polypeptides
|
|
BR112022013730A2
(pt)
*
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
|
|
GB202003277D0
(en)
|
2020-03-06 |
2020-04-22 |
King S College London |
Therapeutic agents
|
|
US20230174638A1
(en)
*
|
2020-05-11 |
2023-06-08 |
Medimmune Limited |
Formulations of anti-il-33 antibodies
|
|
EP4153130A1
(en)
*
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
|
GB202007655D0
(en)
|
2020-05-22 |
2020-07-08 |
King S College London |
Chimeric nkg2d protein
|
|
BR112023019385A2
(pt)
|
2021-03-23 |
2023-12-05 |
King S College London |
Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
GB202214120D0
(en)
|
2022-09-27 |
2022-11-09 |
King S College London |
Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
|
|
EP4389762A1
(en)
|
2022-12-23 |
2024-06-26 |
Ospedale San Raffaele S.r.l. |
Inhibitors of dux4 activity and their use in therapy.
|
|
WO2025140467A1
(zh)
*
|
2023-12-29 |
2025-07-03 |
上海复宏汉霖生物技术股份有限公司 |
稳定的高浓度抗pd-1抗体药物制剂
|
|
WO2025196207A1
(en)
|
2024-03-20 |
2025-09-25 |
King's College London |
Compositions and methods for use in depleting senescent cells and treating aging
|